fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes
Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies. “Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval is an important advance in the treatment of type 2 diabetes,” said Patrick Archdeacon, M.D.

Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control. More than 30 million Americans have type 2 diabetes. Glucagon-like peptide-1 (GLP- 1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar Control.

Mounjaro is administered by injection under the skin once weekly, with the dose adjusted as tolerated to meet blood sugar goals. Patients randomized to receive the maximum recommended dose (15 milligrams) had lowering of their hemoglobin A1c (HbA1c) level.

In trials comparing Mounjaro to other diabetes medications, patients who received the maximum recommended dose had lowering of their HbA1c by 0.5% more than semaglutide. Obesity was common among study participants, with an average body mass index of 32 to 34 kilograms/height in meters squared.
Posted by
cleaner
Tap to copy the Short Url to this post:
bto.sh/n3adbnih 
All Business News on a Single Page. Join for Free →